Recruiting
Who can join AIPeople with VEXAS syndrome.
What is being studied AITests arumakimig (MAS825) versus placebo for VEXAS symptoms and oral glucocorticoid reduction.
Study typeTreatment (drug) · Phase 2
CountriesJapan
VEXAS Syndrome
Browse recruiting and upcoming clinical trials for VEXAS syndrome.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Recruiting
Momelotinib in VEXAS Syndrome
NCT07098936
Who can join AIAdults with genetically confirmed VEXAS syndrome (UBA1 mutation), with or without myelodysplastic syndrome, requiring immunosuppressive therapy.
What is being studied AITests momelotinib treatment for VEXAS syndrome, with or without myelodysplastic syndrome.
Study typeTreatment (drug) · Phase 2
CountriesFrance
Recruiting
Who can join AIAdults (18+) with VEXAS syndrome caused by a UBA1 somatic mutation.
What is being studied AITests safety and tolerability of pacritinib in people with VEXAS syndrome.
Study typeTreatment (drug) · Phase 1
CountriesUnited States
Not yet recruiting
Who can join AIAdults (≥18) with genetically confirmed VEXAS (UBA1 mutation) who are receiving prednisone or prednisolone.
What is being studied AITests momelotinib versus placebo added to glucocorticoids in VEXAS.
Study typeTreatment (drug) · Phase 2/3
CountriesNot posted yet
Recruiting
Who can join AIAdults (18–99 years) with a confirmed diagnosis of VEXAS syndrome (UBA1 pathogenic mutation).
What is being studied AICollects patient questionnaires measuring quality of life, fatigue, and financial toxicity in VEXAS.
Study typeObservational
CountriesItaly
Recruiting
Who can join AIPeople with VEXAS Syndome or other known or suspected autoinflammatory, autoimmune, or rheumatic diseases, their family members, and healthy volunteers.
What is being studied AICollects genetic and blood samples to study genetic causes and immune features of autoinflammatory diseases.
Study typeObservational
CountriesUnited States
Not yet recruiting
Who can join AIAdults older than 50 admitted to a participating Internal Medicine department with unexplained systemic inflammation or blood-cell abnormalities.
What is being studied AICollects clinical data and performs UBA1 genetic testing to identify VEXAS cases.
Study typeObservational
CountriesNot posted yet
Enrolling by invitation
Who can join AIPeople with bone marrow failure disorders (and age‑matched healthy volunteer controls).
What is being studied AICollects multi-omics (DNA/RNA, epigenetics, proteomics) data from blood and bone marrow samples.
Study typeObservational
CountriesUnited States
Recruiting
Who can join AIAdults (18+) with established or suspected VEXAS syndrome who can give informed consent.
What is being studied AICollects real-world clinical data and biospecimens to study VEXAS disease patterns, treatments, and biomarkers.
Study typeRegistry
CountriesGermany
Recruiting
Who can join AIPeople diagnosed with monogenic or polygenic autoinflammatory diseases, including Behçet's disease, Still disease, PFAPA, Schnitzler, VEXAS, spondyloarthritis, Castleman disease, and non-infectious uveitis or scleritis.
What is being studied AICollects clinical, genetic, treatment, and outcome data in people with autoinflammatory diseases.
Study typeRegistry
CountriesAlgeria, Australia, Belgium +19
Not yet recruiting
Who can join AIAdults (≥18) with inflammatory or immune-system conditions, with or without clonal hematopoiesis or related blood disorders (e.g., VEXAS, MDS/MPN, lymphoma, leukemia, MGUS).
What is being studied AICollects clinical, genetic, and outcome data on dysimmune manifestations with or without clonal hematopoiesis.
Study typeRegistry
CountriesFrance